Biopharma | April 16, 2026
Aurobindo’s TheraNym to invest up to $175 million in expanded biologics deal with MSD
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
This development signals a cleanup of Anlon’s borrowing profile and closure of legacy debt facilities
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
The FDA clearance of Zeto New Wave marks the company’s third cleared device, alongside Zeto WR19 and Zeto ONE
Subscribe To Our Newsletter & Stay Updated
